Metabolomics in amyotrophic lateral sclerosis: How far can it take us?

European Journal of Neurology

Volumn 23, Issue 3, 2016, Pages 447-454

  Blasco, H ^a,b,c   Patin, F ^a,b,c   Madji Hounoum, B ^a,b   Gordon, P H ^d   Vourc'h, P ^a,b,c   Andres, C R ^a,b,c   Corcia, P ^a,b,e  

^a CHRU de Tours   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d Northern Navajo Medical Center   (United States)

^e CHU BRETONNEAU   (France)

Author keywords

Amyotrophic lateral sclerosis; Biomarkers; Diagnosis; Metabolomics; Prognosis

Indexed keywords

BIOLOGICAL MARKER; METHIONINE SULFOXIMINE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DRUG METABOLISM; HUMAN; METABOLOMICS; METHODOLOGY; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; SYSTEMATIC REVIEW; METABOLISM; PROCEDURES; STANDARDS;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; METABOLOMICS;

EID: 84959517777     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12956     Document Type: Review

References (38)

1. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009; 8: 94-109.
2. Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012; 13: 1-10.
3. Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol 2015; 126: 803-809.
4. Grieve SM, Menon P, Korgaonkar MS, et al. Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2015; 17: 85-92.
5. Liu CH. Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging. Future Neurol 2015; 10: 49-65.
6. Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012; 13: 263-269.
7. Wang JH, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010; 30: 500-511.
8. Koek MM, Jellema RH, van der Greef J, Tas AC, Hankemeier T. Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 2011; 7: 307-328.
9. Ganesalingam J, Bowser R. The application of biomarkers in clinical trials for motor neuron disease. Biomark Med 2010; 4: 281-297.
10. Wuolikainen A, Hedenstrom M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Lateral Scler 2009; 10: 229-236.
11. Rozen S, Cudkowicz ME, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005; 1: 101-108.
12. Kumar A, Bala L, Kalita J, et al. Metabolomic analysis of serum by (1)H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta 2010; 411: 563-567.
13. Blasco H, Corcia P, Moreau C, et al. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010; 5: e13223.
14. Gray E, Larkin JR, Claridge TD, Talbot K, Sibson NR, Turner MR. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 456-463.
15. Lawton KA, Cudkowicz ME, Brown MV, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler 2012; 13: 110-118.
16. Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 362-370.
17. Wuolikainen A, Moritz T, Marklund SL, Antti H, Andersen PM. Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. PLoS One 2011; 6: e17947.
18. Wuolikainen A, Andersen PM, Moritz T, Marklund SL, Antti H. ALS patients with mutations in the SOD1 gene have a unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol Genet Metab 2012; 105: 472-478.
19. Blasco H, Nadal-Desbarats L, Pradat PF, et al. Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology 2014; 82: 1167-1174.
20. Blasco H, Corcia P, Pradat PF, et al. Metabolomics in cerebrospinal fluid of patients with amyotrophic lateral sclerosis: an untargeted approach via high-resolution mass spectrometry. J Proteome Res 2013; 12: 3746-3754.
21. Blasco H, Blaszczynski J, Billaut JC, et al. Comparative analysis of targeted metabolomics: dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. J Biomed Inform 2015; 53: 291-299.
22. Bowser R, Lacomis D. Applying proteomics to the diagnosis and treatment of ALS and related diseases. Muscle Nerve 2009; 40: 753-762.
23. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-78.
24. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
25. Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. J Nutr 2001; 131: 846S-850S.
26. Contrusciere V, Paradisi S, Matteucci A, Malchiodi-Albedi F. Branched-chain amino acids induce neurotoxicity in rat cortical cultures. Neurotox Res 2010; 17: 392-398.
27. Hutson SM, Fenstermacher D, Mahar C. Role of mitochondrial transamination in branched chain amino acid metabolism. J Biol Chem 1988; 263: 3618-3625.
28. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J Nutr 2006; 136: 207S-211S.
29. Engskog MK, Karlsson O, Haglof J, et al. The cyanobacterial amino acid beta-N-methylamino-l-alanine perturbs the intermediary metabolism in neonatal rats. Toxicology 2013; 312: 6-11.
30. Bame M, Grier RE, Needleman R, Brusilow WS. Amino acids as biomarkers in the SOD1(G93A) mouse model of ALS. Biochim Biophys Acta 2014; 1842: 79-87.
31. Valbuena GN, Rizzardini M, Cimini S, et al. Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol Neurobiol 2015; doi: 10.1007/s12035-015-9165-7.
32. Joardar A, Menzl J, Podolsky TC, et al. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. Hum Mol Genet 2015; 24: 1741-1754.
33. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 2008; 8: 479-494.
34. Crews B, Wikoff WR, Patti GJ, et al. Variability analysis of human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based metabolomics data. Anal Chem 2009; 81: 8538-8544.
35. Shevchenko G, Konzer A, Musunuri S, Bergquist J. Neuroproteomics tools in clinical practice. Biochim Biophys Acta 2015; 1854: 705-717.
36. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014; 13: 1127-1138.
37. Beghi E, Pupillo E, Bonito V, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 397-405.
38. Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 406-413.